Products

prolaio eVO2peak Module
Prolaio
Cardiology AI

See all 1 product →

About Prolaio

Prolaio is a clinical intelligence company that leverages advanced data science and artificial intelligence to revolutionize cardiovascular care and research. The company’s platform integrates a connected system powered by real-world patient data, enabling personalized care plans and improved outcomes for individuals with heart conditions.

For physicians, Prolaio’s technology offers a means to move beyond episodic data, providing a more comprehensive and continuous understanding of a patient’s heart health. This approach supports early intervention points, evidence-based care plans, and the proactive management of conditions like heart failure. The platform also plays a crucial role in clinical research and drug development by optimizing study design, increasing statistical power, and enhancing confidence through better data, ultimately aiming to accelerate therapeutic discovery and deliver precision cardiovascular care.

Founded by experts in cardiovascular medicine and data science, Prolaio is committed to addressing cardiovascular disease, the leading cause of death worldwide, by transforming real-world heart data into faster discovery and precision care. The company’s innovative approach focuses on patient-centered, science-driven solutions, utilizing digital biomarkers to predict physiological changes and empower more timely and effective interventions.

Focus Areas

Precision cardiology cardiovascular care clinical research real-world data advanced analytics AI patient monitoring drug development heart disease heart failure hypertrophic cardiomyopathy (HCM)

Business Intelligence

TechnologyCloud-native platform leveraging advanced data science, proprietary algorithms, and real-world patient data. Utilizes AWS, Amazon S3, and Amazon CloudFront. Focuses on digital biomarkers and continuous physiological data streams from wearable biosensors.

What Physicians Need to Know

Precision Cardiology & Cardiovascular Care
Prolaio is dedicated to revolutionizing cardiovascular care by integrating a connected platform powered by advanced data science, enabling personalized care and improved patient outcomes. They focus on proactive and continuous patient management, extending beyond traditional episodic clinic visits.
Real-World Data & Advanced Analytics/AI
A core differentiator, Prolaio unlocks access to continuous, predictive, and shareable high-density heart data. They leverage cutting-edge analytics and machine learning algorithms to identify high-risk individuals, predict potential complications, and personalize treatment plans. Their platform includes FDA-cleared software and proprietary algorithms, built upon one of the industry's largest curated cardiovascular data sets.
Clinical Research Acceleration
Prolaio significantly accelerates clinical research by facilitating eligible patient identification, providing deep, high-density data insights, and reducing variability. Their technology-enabled platform optimizes study design, decreases overhead, and enhances confidence in trial results, ultimately transforming the pace of drug development and patient outcomes.
Comprehensive Patient Monitoring
They offer improved, near real-time monitoring through wearable devices and remote systems that track vital signs like heart rate and rhythm. Their comprehensive kit for patients includes a wrist monitor, smart blood pressure cuff, smart scale, a pre-loaded phone with their app, and ECG patches, providing 24/7 connected heart care.
Drug Development Support
Prolaio's platform and extensive data sets are instrumental in modernizing cardiovascular drug development. By integrating high-density patient data and advanced analytics, they help partners design better trials, discover more targeted medicines, and accelerate the development of novel therapies.
Specialization in Heart Failure & HCM
Prolaio provides targeted solutions for heart failure, including Hospital-to-Home Transition Care with continuous monitoring and risk assessment. They are pioneers in managing Hypertrophic Cardiomyopathy (HCM) with technology, enabling early detection, personalized care, and aiming to make the disease more predictable and systematic.
Key Differentiators
Prolaio stands out due to its focus on high-density, continuous real-world heart data, FDA-cleared software with proprietary AI algorithms, and its ability to unite patients, providers, and researchers on a single intuitive platform. Their pioneering work in AI-based analytics and extensive curated cardiovascular data sets, coupled with ISO 13485:2016 and MDSAP certifications, underscore their commitment to quality and innovation.
Technology Stack
Their technology stack includes wearable devices (wrist monitors, smart BP cuffs, smart scales, ECG patches/biosensors), a proprietary mobile application for patient engagement, telemedicine platforms for enhanced communication, advanced analytics and machine learning algorithms for predictive insights, and a secure, cloud-based 'Prolaio Monitoring Workbench' for clinicians.
Physician Tip

For physicians, Prolaio offers unparalleled data-driven insights, enabling more informed clinical decisions and the ability to personalize treatment plans based on continuous, real-world patient data. The platform facilitates early detection and timely intervention, potentially reducing hospitalizations and emergency visits, especially for conditions like heart failure and HCM. Its FDA-cleared and rigorously validated technology builds trust, while the integrated approach simplifies workflows and enhances patient engagement through remote monitoring and communication tools. This allows for a more proactive and effective management of cardiovascular conditions.

Prolaio's platform is designed to integrate high-density patient data and proprietary algorithms to deliver outcome-driven insights. While specific third-party integrations are not explicitly detailed beyond their own comprehensive kit, their acquisition by Kardigan indicates a strategic integration into drug development pipelines. Their platform is built to unite patients, providers, and researchers, suggesting a capability for data sharing and collaboration within the healthcare ecosystem.

Products by Prolaio

1 product in the directory

prolaio eVO2peak Module
Prolaio
Cardiology AI

Videos

News, demos, and interviews about Prolaio.

Loading videos...

Videos load interactively. If none appear, search YouTube for Prolaio →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

Prolaio offers an FDA-cleared remote monitoring platform that captures continuous, high-density cardiovascular data. This platform includes a kit with devices like a wrist monitor, smart blood pressure cuff, smart scale, a pre-loaded phone with their app, and ECG patches, designed for proactive care and personalized insights. They also provide an FDA-cleared eVO2peak Module for estimating peak oxygen consumption.
Prolaio utilizes real-world heart data, advanced analytics, and proprietary AI algorithms to provide outcome-driven insights for cardiovascular research and drug development. Their platform helps accelerate clinical trials by optimizing study design, identifying eligible patients, reducing overhead, and increasing statistical power through high-density data insights. This approach aims to transform real-world data into faster therapeutic discovery and precision cardiovascular care.
Prolaio offers specialized solutions for Hospital-to-Home Transition Care for heart failure patients and continuous monitoring for Hypertrophic Cardiomyopathy (HCM). For HCM, their program provides a wearable monitoring solution with devices and a mobile app to track symptoms and analyze data for predictive insights. This enables care teams to proactively manage patient status and intervene if increasing risks are detected.
Prolaio's software is FDA-cleared, and the company is compliant with 21CFR Part 11 for electronic records and signatures. They are also ISO 13485:2016 certified for medical device quality management systems and MDSAP certified, ensuring rigorous quality and global standards. Prolaio employs reasonable and appropriate steps to protect personal information from unauthorized access, use, disclosure, alteration, and destruction, with data fully stored and processed in the United States.
Prolaio was acquired by Kardigan, a cardiovascular drug development company, in March 2025, but continues to function independently as a clinical intelligence company. This acquisition integrates Prolaio's data collection and analytics platform into Kardigan's R&D, enhancing drug development and expanding Prolaio's reach to more patients and providers. The partnership provides long-term stability and leverages Kardigan's operational scale and resources to accelerate cardiovascular innovation.
Prolaio offers a 'free-to-patients' wearable monitoring solution for conditions like HCM, aiming to make care accessible. For clinical intelligence and research services, their platform helps reduce overall trial costs and administrative overhead, though specific pricing details for healthcare organizations are not publicly disclosed. Prolaio provides 'always-on support' for patients and technical support for study participants, and their platform is designed to simplify workflows for care teams.
While direct EHR integration capabilities are not explicitly detailed, Prolaio's FDA-cleared software delivers outcome-driven insights to empower care teams and aims to simplify research workflows. The platform provides scheduled reports and a 'Monitoring Workbench' for care teams to track patient data, suggesting a system designed to integrate with existing clinical practices and inform treatment decisions. The company's focus on 'uniting patients, providers, and researchers on a single, intuitive platform' implies a design for seamless incorporation into healthcare ecosystems.

Related Companies

Stanford University, through its online learning platform Stanford Online (online.stanford.edu), provides a wide array of educational opportunities, including those focused on Artificial Intelligence (AI) in healthcare. Stanford Online aims to extend the university’s academic excellence and breakthrough research to a global audience, offering programs taught by Stanford faculty and industry experts. These offerings range from […]

Radin Health offers a comprehensive suite of AI-powered, cloud-based solutions designed to enhance operational efficiency across all stages of the radiology workflow. Their platform integrates a Radiology Information System (RIS), Picture Archiving and Communication System (PACS), AI-driven Dictation, and RADIN SELECT for workflow management. These solutions aim to improve efficiency and productivity for administrators, medical […]

Google Workspace provides a comprehensive suite of secure online productivity and collaboration tools designed for various organizational sizes, including businesses, enterprises, and frontline workers. For physicians and healthcare professionals, Google Workspace offers a secure environment for communication, data storage, and document management, which is crucial for maintaining patient confidentiality and operational efficiency. The platform integrates […]

Pacmed is an Amsterdam-based clinical intelligence company that develops and implements AI solutions to improve hospital care, with a particular focus on the Intensive Care Unit (ICU). The company’s core product, Pacmed Critical, is an AI platform designed to optimize ICU capacity, enhance patient outcomes, and provide data-driven insights for medical professionals. This platform integrates […]

AiZtech Labs is a pioneering deep tech company that leverages AI to transform healthcare by providing accessible and rapid screening tools. Their mission is to enhance the quality of life for one billion people by blending world-class AI research with human-centered design. The company’s flagship platform, iSelfie BioSignals, utilizes a smartphone camera to detect digital […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.